256 related articles for article (PubMed ID: 18635597)
1. Costs and quality of life of patients with ankylosing spondylitis in Hong Kong.
Zhu TY; Tam LS; Lee VW; Hwang WW; Li TK; Lee KK; Li EK
Rheumatology (Oxford); 2008 Sep; 47(9):1422-5. PubMed ID: 18635597
[TBL] [Abstract][Full Text] [Related]
2. Costs and quality of life of patients with ankylosing spondylitis in Canada.
Kobelt G; Andlin-Sobocki P; Maksymowych WP
J Rheumatol; 2006 Feb; 33(2):289-95. PubMed ID: 16465660
[TBL] [Abstract][Full Text] [Related]
3. Systemic lupus erythematosus with neuropsychiatric manifestation incurs high disease costs: a cost-of-illness study in Hong Kong.
Zhu TY; Tam LS; Lee VW; Lee KK; Li EK
Rheumatology (Oxford); 2009 May; 48(5):564-8. PubMed ID: 19269959
[TBL] [Abstract][Full Text] [Related]
4. The burden of ankylosing spondylitis and the cost-effectiveness of treatment with infliximab (Remicade).
Kobelt G; Andlin-Sobocki P; Brophy S; Jönsson L; Calin A; Braun J
Rheumatology (Oxford); 2004 Sep; 43(9):1158-66. PubMed ID: 15226514
[TBL] [Abstract][Full Text] [Related]
5. [RAISE study observational and cross sectional study to evaluate the actual reality of the socio-economic impact of ankylosing spondylitis].
Miranda L; Negreiro F; Queiroz MJ; Silva C
Acta Reumatol Port; 2008; 33(2):189-97. PubMed ID: 18604185
[TBL] [Abstract][Full Text] [Related]
6. The unmet need for anti-tumour necrosis factor (anti-TNF) therapy in ankylosing spondylitis.
Barkham N; Kong KO; Tennant A; Fraser A; Hensor E; Keenan AM; Emery P
Rheumatology (Oxford); 2005 Oct; 44(10):1277-81. PubMed ID: 16105913
[TBL] [Abstract][Full Text] [Related]
7. Societal costs of rheumatoid arthritis in Hong Kong: a prevalence-based cost-of-illness study.
Zhu TY; Tam LS; Li EK
Rheumatology (Oxford); 2011 Jul; 50(7):1293-301. PubMed ID: 21330341
[TBL] [Abstract][Full Text] [Related]
8. Large differences in cost of illness and wellbeing between patients with fibromyalgia, chronic low back pain, or ankylosing spondylitis.
Boonen A; van den Heuvel R; van Tubergen A; Goossens M; Severens JL; van der Heijde D; van der Linden S
Ann Rheum Dis; 2005 Mar; 64(3):396-402. PubMed ID: 15271773
[TBL] [Abstract][Full Text] [Related]
9. Physical function and health-related quality of life of Spanish patients with ankylosing spondylitis.
Ariza-Ariza R; Hernández-Cruz B; Navarro-Sarabia F
Arthritis Rheum; 2003 Aug; 49(4):483-7. PubMed ID: 12910553
[TBL] [Abstract][Full Text] [Related]
10. Socioeconomic burden of psoriatic arthritis in Hong Kong: direct and indirect costs and the influence of disease pattern.
Zhu TY; Tam LS; Leung YY; Kwok LW; Wong KC; Yu T; Kun EW; Li EK
J Rheumatol; 2010 Jun; 37(6):1214-20. PubMed ID: 20360186
[TBL] [Abstract][Full Text] [Related]
11. A longitudinal study of disease activity and functional status in a hospital cohort of patients with ankylosing spondylitis.
Robertson LP; Davis MJ
Rheumatology (Oxford); 2004 Dec; 43(12):1565-8. PubMed ID: 15353608
[TBL] [Abstract][Full Text] [Related]
12. Functional disability predicts total costs in patients with ankylosing spondylitis.
Ward MM
Arthritis Rheum; 2002 Jan; 46(1):223-31. PubMed ID: 11817595
[TBL] [Abstract][Full Text] [Related]
13. Costs and quality of life of multiple sclerosis in Austria.
Kobelt G; Berg J; Lindgren P; Plesnilla C; Baumhackl U; Berger T; Kolleger H; Vass K
Eur J Health Econ; 2006 Sep; 7 Suppl 2():S14-23. PubMed ID: 17310339
[TBL] [Abstract][Full Text] [Related]
14. Costs and work limitation of patients with ankylosing spondylitis in China.
Tu L; Rai JC; Cao S; Lin Z; Hu Z; Gu J
Clin Exp Rheumatol; 2014; 32(5):661-6. PubMed ID: 25234798
[TBL] [Abstract][Full Text] [Related]
15. The cost-effectiveness of infliximab (Remicade) in the treatment of ankylosing spondylitis in Canada.
Kobelt G; Andlin-Sobocki P; Maksymowych WP
J Rheumatol; 2006 Apr; 33(4):732-40. PubMed ID: 16583476
[TBL] [Abstract][Full Text] [Related]
16. Reference centile charts for measures of disease activity, functional impairment, and metrology in ankylosing spondylitis.
Taylor AL; Balakrishnan C; Calin A
Arthritis Rheum; 1998 Jun; 41(6):1119-25. PubMed ID: 9627023
[TBL] [Abstract][Full Text] [Related]
17. Costs and quality of life of multiple sclerosis in Switzerland.
Kobelt G; Berg J; Lindgren P; Gerfin A; Lutz J
Eur J Health Econ; 2006 Sep; 7 Suppl 2():S86-95. PubMed ID: 17310338
[TBL] [Abstract][Full Text] [Related]
18. [Social costs of the most common inflammatory rheumatic diseases in Mexico from the patient's perspective].
Mould-Quevedo J; Peláez-Ballestas I; Vázquez-Mellado J; Terán-Estrada L; Esquivel-Valerio J; Ventura-Ríos L; Aceves-Avila FJ; Bernard-Medina AG; Goycochea-Robles MV; Hernández-Garduño A; Burgos-Vargas R; Shumski C; Garza-Elizondo M; Ramos-Remus C; Espinoza-Villalpando J; Alvarez-Hernández E; Flores-Alvarado D; Rodríguez-Amado J; Casasola-Vargas J; Skinner-Taylor C;
Gac Med Mex; 2008; 144(3):225-31. PubMed ID: 18714591
[TBL] [Abstract][Full Text] [Related]
19. The impact of flare on disease costs of patients with systemic lupus erythematosus.
Zhu TY; Tam LS; Lee VW; Lee KK; Li EK
Arthritis Rheum; 2009 Sep; 61(9):1159-67. PubMed ID: 19714597
[TBL] [Abstract][Full Text] [Related]
20. Is disease severity in ankylosing spondylitis genetically determined?
Hamersma J; Cardon LR; Bradbury L; Brophy S; van der Horst-Bruinsma I; Calin A; Brown MA
Arthritis Rheum; 2001 Jun; 44(6):1396-400. PubMed ID: 11407700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
